Chen Jessie, Long Jessica E, Vannice Kirsten, Shewchuk Tanya, Kumar Supriya, Duncan Steele A, Zaidi Anita K M
Enteric and Diarrheal Diseases, Global Health, Bill & Melinda Gates Foundation, Seattle, Washington, USA.
Open Forum Infect Dis. 2023 Jun 2;10(Suppl 1):S74-S81. doi: 10.1093/ofid/ofad055. eCollection 2023 May.
Typhoid fever is a significant global health problem that impacts people living in areas without access to clean water and sanitation. However, collaborative international partnerships and new research have improved both knowledge of the burden in countries with endemic disease and the tools for improved surveillance, including environmental surveillance. Two typhoid conjugate vaccines (TCVs) have achieved World Health Organization prequalification, with several more in the development pipeline. Despite hurdles posed by the coronavirus disease 2019 pandemic, multiple TCV efficacy trials have been conducted in high-burden countries, and data indicate that TCVs provide a high degree of protection from typhoid fever, are safe to use in young children, provide lasting protection, and have the potential to combat typhoid antimicrobial resistance. Now is the time to double down on typhoid control and elimination by sustaining progress made through water, sanitation, and hygiene improvements and accelerating TCV introduction in high-burden locations.
伤寒热是一个重大的全球健康问题，影响着生活在无法获得清洁水和卫生设施地区的人们。然而，国际合作伙伴关系和新的研究改善了对伤寒流行国家疾病负担的了解以及包括环境监测在内的改进监测工具。两种伤寒结合疫苗（TCV）已获得世界卫生组织的预认证，还有几种正在研发中。尽管2019冠状病毒病大流行带来了障碍，但在高负担国家已经开展了多项TCV疗效试验，数据表明TCV能提供高度的伤寒热防护，对幼儿使用安全，能提供持久保护，并有潜力对抗伤寒抗菌耐药性。现在是时候通过维持在改善水、卫生和个人卫生方面取得的进展，并加速在高负担地区引入TCV，来加倍努力控制和消除伤寒了。
